Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT02420977
Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer
Overview
This research is being done to see if an investigational radioactive imaging agent (radiotracer) called 18F-DCFPyL can help us find prostate cancer at its original site in the prostate gland and in distant sites (bone, lymph nodes) in men diagnosed with prostate cancer before surgery.
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase
Early Phase 1
Contacts
Curtiland Deville, M.D. (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT02420977Drug / Compound
DCFPyL
Isotope(s):
FLUORINE-18
Radioisotope: F-18
Theranostic Role: PET Imaging
T1/2 (Half-Life): 1.8 Hours
Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
Energy: Eβ+ 635 keV
Range: N/A
Decay Daughters: O18 (Stable)
Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
Target(s):
- PSMA
Ligand Class: Small Molecules
Eligibility
Inclusion
- At least 10 days after most recent prostate biopsy
- Newly diagnosed prostate cancer pathologically proven by prostate biopsy
- Key inclusion criteria (the entire list of inclusion and exclusion criteria will appear later in section 4 of the protocol)
- Patients considered as candidates for and medically fit to undergo radiation and ADT
- Prostate biopsy histology grade ≥ Gleason 8-10
Exclusion
- Hemorrhagic cystitis or active prostatitis
- Prior pelvic external beam radiation therapy or brachytherapy
- Chemotherapy for prostate cancer
- Investigational therapy for prostate cancer
- Hormone deprivation therapy
Share your feedback
Help us improve your experience